nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyldopa—COMT—hypertension	0.172	0.611	CbGaD
Methyldopa—ADRA2A—hypertension	0.109	0.389	CbGaD
Methyldopa—Isoprenaline—Pindolol—hypertension	0.0771	0.53	CrCrCtD
Methyldopa—Isoprenaline—Labetalol—hypertension	0.0683	0.47	CrCrCtD
Methyldopa—SLC15A1—Fosinopril—hypertension	0.0365	0.102	CbGbCtD
Methyldopa—SLC15A1—Quinapril—hypertension	0.0365	0.102	CbGbCtD
Methyldopa—SLC15A1—Benazepril—hypertension	0.0325	0.0906	CbGbCtD
Methyldopa—SLC15A1—Moexipril—hypertension	0.0325	0.0906	CbGbCtD
Methyldopa—SLC15A1—Trandolapril—hypertension	0.0246	0.0686	CbGbCtD
Methyldopa—SLC15A1—Perindopril—hypertension	0.0225	0.0628	CbGbCtD
Methyldopa—ADRA2A—Guanabenz—hypertension	0.0207	0.0576	CbGbCtD
Methyldopa—ADRA2A—Guanfacine—hypertension	0.0192	0.0536	CbGbCtD
Methyldopa—SLC15A1—Enalapril—hypertension	0.0187	0.052	CbGbCtD
Methyldopa—SLC15A1—Ramipril—hypertension	0.0187	0.052	CbGbCtD
Methyldopa—SLC15A1—Lisinopril—hypertension	0.0187	0.052	CbGbCtD
Methyldopa—ADRA2A—Fenoldopam—hypertension	0.0164	0.0455	CbGbCtD
Methyldopa—ADRA2A—Doxazosin—hypertension	0.0151	0.042	CbGbCtD
Methyldopa—SLC15A1—Captopril—hypertension	0.014	0.0389	CbGbCtD
Methyldopa—ADRA2A—Prazosin—hypertension	0.0124	0.0345	CbGbCtD
Methyldopa—ADRA2A—Carvedilol—hypertension	0.0107	0.0298	CbGbCtD
Methyldopa—ADRA2A—Clonidine—hypertension	0.00939	0.0262	CbGbCtD
Methyldopa—DDC—brainstem—hypertension	0.000786	0.0593	CbGeAlD
Methyldopa—DDC—nephron tubule—hypertension	0.000714	0.0539	CbGeAlD
Methyldopa—COMT—cardiac ventricle—hypertension	0.000685	0.0517	CbGeAlD
Methyldopa—DDC—kidney—hypertension	0.000628	0.0474	CbGeAlD
Methyldopa—DDC—cortex of kidney—hypertension	0.000611	0.0461	CbGeAlD
Methyldopa—SLC15A1—nephron tubule—hypertension	0.000531	0.0401	CbGeAlD
Methyldopa—COMT—brainstem—hypertension	0.00052	0.0392	CbGeAlD
Methyldopa—DDC—adrenal gland—hypertension	0.000507	0.0383	CbGeAlD
Methyldopa—COMT—nephron tubule—hypertension	0.000472	0.0356	CbGeAlD
Methyldopa—SLC15A1—kidney—hypertension	0.000467	0.0352	CbGeAlD
Methyldopa—COMT—adrenal cortex—hypertension	0.000465	0.0351	CbGeAlD
Methyldopa—Metyrosine—TH—hypertension	0.000451	0.116	CrCbGaD
Methyldopa—COMT—heart—hypertension	0.00045	0.0339	CbGeAlD
Methyldopa—COMT—smooth muscle tissue—hypertension	0.000446	0.0337	CbGeAlD
Methyldopa—DDC—endocrine gland—hypertension	0.00044	0.0332	CbGeAlD
Methyldopa—COMT—decidua—hypertension	0.000437	0.033	CbGeAlD
Methyldopa—COMT—cardiovascular system—hypertension	0.000424	0.032	CbGeAlD
Methyldopa—COMT—kidney—hypertension	0.000415	0.0313	CbGeAlD
Methyldopa—COMT—cortex of kidney—hypertension	0.000404	0.0305	CbGeAlD
Methyldopa—DDC—central nervous system—hypertension	0.000396	0.0299	CbGeAlD
Methyldopa—COMT—cardiac atrium—hypertension	0.000384	0.029	CbGeAlD
Methyldopa—COMT—medulla oblongata—hypertension	0.000362	0.0274	CbGeAlD
Methyldopa—COMT—adrenal gland—hypertension	0.000336	0.0253	CbGeAlD
Methyldopa—SLC15A1—endocrine gland—hypertension	0.000327	0.0247	CbGeAlD
Methyldopa—COMT—endocrine gland—hypertension	0.000291	0.022	CbGeAlD
Methyldopa—Mesalazine—IKBKB—hypertension	0.00028	0.072	CrCbGaD
Methyldopa—COMT—central nervous system—hypertension	0.000262	0.0198	CbGeAlD
Methyldopa—ADRA2A—heart—hypertension	0.000229	0.0173	CbGeAlD
Methyldopa—Isoprenaline—PIK3R1—hypertension	0.000226	0.058	CrCbGaD
Methyldopa—ADRA2A—decidua—hypertension	0.000223	0.0168	CbGeAlD
Methyldopa—ADRA2A—cortex of kidney—hypertension	0.000206	0.0155	CbGeAlD
Methyldopa—ADRA2A—cardiac atrium—hypertension	0.000196	0.0148	CbGeAlD
Methyldopa—ADRA2A—medulla oblongata—hypertension	0.000185	0.0139	CbGeAlD
Methyldopa—ADRA2A—adrenal gland—hypertension	0.000171	0.0129	CbGeAlD
Methyldopa—Isoprenaline—ADRBK1—hypertension	0.000163	0.0419	CrCbGaD
Methyldopa—ADRA2A—endocrine gland—hypertension	0.000148	0.0112	CbGeAlD
Methyldopa—Dopamine—DBH—hypertension	0.000147	0.0378	CrCbGaD
Methyldopa—Epinephrine—ADRBK1—hypertension	0.000137	0.0352	CrCbGaD
Methyldopa—ADRA2A—central nervous system—hypertension	0.000134	0.0101	CbGeAlD
Methyldopa—Levonordefrin—ADRA2B—hypertension	0.000131	0.0338	CrCbGaD
Methyldopa—Aminosalicylic Acid—ALOX5—hypertension	0.000128	0.0329	CrCbGaD
Methyldopa—Levonordefrin—SLC6A2—hypertension	0.000115	0.0297	CrCbGaD
Methyldopa—Mesalazine—ALOX5—hypertension	0.0001	0.0258	CrCbGaD
Methyldopa—Droxidopa—ADRA2B—hypertension	9.26e-05	0.0238	CrCbGaD
Methyldopa—Isoetarine—ADRB1—hypertension	8.87e-05	0.0228	CrCbGaD
Methyldopa—Aminosalicylic Acid—MPO—hypertension	8.24e-05	0.0212	CrCbGaD
Methyldopa—Levonordefrin—ADRA1A—hypertension	8.13e-05	0.0209	CrCbGaD
Methyldopa—Droxidopa—SLC6A2—hypertension	8.13e-05	0.0209	CrCbGaD
Methyldopa—Norepinephrine—ADRA2B—hypertension	7.79e-05	0.02	CrCbGaD
Methyldopa—Isoetarine—ADRB2—hypertension	7.46e-05	0.0192	CrCbGaD
Methyldopa—Epinephrine—ADRA2B—hypertension	7.07e-05	0.0182	CrCbGaD
Methyldopa—Norepinephrine—SLC6A2—hypertension	6.85e-05	0.0176	CrCbGaD
Methyldopa—Mesalazine—MPO—hypertension	6.46e-05	0.0166	CrCbGaD
Methyldopa—Dopamine—SLC6A2—hypertension	6.36e-05	0.0164	CrCbGaD
Methyldopa—Levonordefrin—ADRA2A—hypertension	5.76e-05	0.0148	CrCbGaD
Methyldopa—Mesalazine—PPARG—hypertension	5.74e-05	0.0148	CrCbGaD
Methyldopa—Droxidopa—ADRA1A—hypertension	5.73e-05	0.0147	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS1—hypertension	5.4e-05	0.0139	CrCbGaD
Methyldopa—Dopamine—COMT—hypertension	4.98e-05	0.0128	CrCbGaD
Methyldopa—Norepinephrine—ADRA1A—hypertension	4.82e-05	0.0124	CrCbGaD
Methyldopa—Epinephrine—ADRA1A—hypertension	4.38e-05	0.0113	CrCbGaD
Methyldopa—Mesalazine—PTGS1—hypertension	4.24e-05	0.0109	CrCbGaD
Methyldopa—Droxidopa—ADRA2A—hypertension	4.06e-05	0.0104	CrCbGaD
Methyldopa—Droxidopa—ADRB1—hypertension	4.05e-05	0.0104	CrCbGaD
Methyldopa—L-DOPA—DRD3—hypertension	3.74e-05	0.00963	CrCbGaD
Methyldopa—Dopamine—HTR7—hypertension	3.7e-05	0.00952	CrCbGaD
Methyldopa—Isoprenaline—ADRB1—hypertension	3.68e-05	0.00947	CrCbGaD
Methyldopa—Dopamine—DRD3—hypertension	3.48e-05	0.00895	CrCbGaD
Methyldopa—Norepinephrine—ADRA2A—hypertension	3.41e-05	0.00878	CrCbGaD
Methyldopa—Norepinephrine—ADRB1—hypertension	3.41e-05	0.00877	CrCbGaD
Methyldopa—Droxidopa—ADRB2—hypertension	3.41e-05	0.00877	CrCbGaD
Methyldopa—Dopamine—SLC6A3—hypertension	3.24e-05	0.00833	CrCbGaD
Methyldopa—Dopamine—ADRB1—hypertension	3.17e-05	0.00816	CrCbGaD
Methyldopa—Epinephrine—ADRA2A—hypertension	3.1e-05	0.00797	CrCbGaD
Methyldopa—Isoprenaline—ADRB2—hypertension	3.1e-05	0.00797	CrCbGaD
Methyldopa—Epinephrine—ADRB1—hypertension	3.1e-05	0.00796	CrCbGaD
Methyldopa—Aminosalicylic Acid—PTGS2—hypertension	3.09e-05	0.00794	CrCbGaD
Methyldopa—Epinephrine—TNF—hypertension	2.94e-05	0.00755	CrCbGaD
Methyldopa—Norepinephrine—ADRB2—hypertension	2.87e-05	0.00738	CrCbGaD
Methyldopa—Vomiting—Propranolol—hypertension	2.81e-05	0.000223	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Irbesartan—hypertension	2.81e-05	0.000223	CcSEcCtD
Methyldopa—Dizziness—Carvedilol—hypertension	2.8e-05	0.000223	CcSEcCtD
Methyldopa—Diarrhoea—Nifedipine—hypertension	2.8e-05	0.000222	CcSEcCtD
Methyldopa—Constipation—Perindopril—hypertension	2.79e-05	0.000222	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Losartan—hypertension	2.79e-05	0.000222	CcSEcCtD
Methyldopa—Hypersensitivity—Valsartan—hypertension	2.79e-05	0.000222	CcSEcCtD
Methyldopa—Rash—Propranolol—hypertension	2.79e-05	0.000221	CcSEcCtD
Methyldopa—Dermatitis—Propranolol—hypertension	2.79e-05	0.000221	CcSEcCtD
Methyldopa—Body temperature increased—Trandolapril—hypertension	2.78e-05	0.000221	CcSEcCtD
Methyldopa—Diarrhoea—Verapamil—hypertension	2.78e-05	0.000221	CcSEcCtD
Methyldopa—Constipation—Irbesartan—hypertension	2.78e-05	0.000221	CcSEcCtD
Methyldopa—Dizziness—Doxazosin—hypertension	2.77e-05	0.00022	CcSEcCtD
Methyldopa—Body temperature increased—Enalapril—hypertension	2.77e-05	0.00022	CcSEcCtD
Methyldopa—Constipation—Hydrochlorothiazide—hypertension	2.76e-05	0.000219	CcSEcCtD
Methyldopa—Paraesthesia—Losartan—hypertension	2.75e-05	0.000218	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Furosemide—hypertension	2.74e-05	0.000218	CcSEcCtD
Methyldopa—Arthralgia—Ramipril—hypertension	2.74e-05	0.000217	CcSEcCtD
Methyldopa—Myalgia—Ramipril—hypertension	2.74e-05	0.000217	CcSEcCtD
Methyldopa—Dizziness—Fosinopril—hypertension	2.74e-05	0.000217	CcSEcCtD
Methyldopa—Body temperature increased—Telmisartan—hypertension	2.73e-05	0.000217	CcSEcCtD
Methyldopa—Dizziness—Eplerenone—hypertension	2.72e-05	0.000216	CcSEcCtD
Methyldopa—Vomiting—Indapamide—hypertension	2.72e-05	0.000216	CcSEcCtD
Methyldopa—Vomiting—Diltiazem—hypertension	2.72e-05	0.000216	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Ramipril—hypertension	2.72e-05	0.000216	CcSEcCtD
Methyldopa—Asthenia—Valsartan—hypertension	2.72e-05	0.000216	CcSEcCtD
Methyldopa—Constipation—Furosemide—hypertension	2.72e-05	0.000216	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Betaxolol—hypertension	2.71e-05	0.000215	CcSEcCtD
Methyldopa—Asthenia—Olmesartan—hypertension	2.7e-05	0.000215	CcSEcCtD
Methyldopa—Dizziness—Nifedipine—hypertension	2.7e-05	0.000214	CcSEcCtD
Methyldopa—Rash—Indapamide—hypertension	2.7e-05	0.000214	CcSEcCtD
Methyldopa—Rash—Diltiazem—hypertension	2.7e-05	0.000214	CcSEcCtD
Methyldopa—Dermatitis—Diltiazem—hypertension	2.7e-05	0.000214	CcSEcCtD
Methyldopa—Dermatitis—Indapamide—hypertension	2.7e-05	0.000214	CcSEcCtD
Methyldopa—Vomiting—Carvedilol—hypertension	2.7e-05	0.000214	CcSEcCtD
Methyldopa—Dizziness—Verapamil—hypertension	2.69e-05	0.000214	CcSEcCtD
Methyldopa—Constipation—Betaxolol—hypertension	2.69e-05	0.000213	CcSEcCtD
Methyldopa—Headache—Indapamide—hypertension	2.68e-05	0.000213	CcSEcCtD
Methyldopa—Headache—Diltiazem—hypertension	2.68e-05	0.000213	CcSEcCtD
Methyldopa—Arthralgia—Timolol—hypertension	2.68e-05	0.000213	CcSEcCtD
Methyldopa—Myalgia—Timolol—hypertension	2.68e-05	0.000213	CcSEcCtD
Methyldopa—Rash—Carvedilol—hypertension	2.67e-05	0.000212	CcSEcCtD
Methyldopa—Dermatitis—Carvedilol—hypertension	2.67e-05	0.000212	CcSEcCtD
Methyldopa—Vomiting—Doxazosin—hypertension	2.67e-05	0.000212	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Timolol—hypertension	2.66e-05	0.000211	CcSEcCtD
Methyldopa—Hypersensitivity—Clonidine—hypertension	2.66e-05	0.000211	CcSEcCtD
Methyldopa—Body temperature increased—Captopril—hypertension	2.66e-05	0.000211	CcSEcCtD
Methyldopa—Isoprenaline—CYP1A1—hypertension	2.66e-05	0.00683	CrCbGaD
Methyldopa—Headache—Carvedilol—hypertension	2.66e-05	0.000211	CcSEcCtD
Methyldopa—Rash—Doxazosin—hypertension	2.64e-05	0.00021	CcSEcCtD
Methyldopa—Dermatitis—Doxazosin—hypertension	2.64e-05	0.00021	CcSEcCtD
Methyldopa—Vomiting—Fosinopril—hypertension	2.63e-05	0.000209	CcSEcCtD
Methyldopa—Nausea—Propranolol—hypertension	2.63e-05	0.000209	CcSEcCtD
Methyldopa—Oedema—Ramipril—hypertension	2.63e-05	0.000208	CcSEcCtD
Methyldopa—Headache—Doxazosin—hypertension	2.63e-05	0.000208	CcSEcCtD
Methyldopa—Constipation—Losartan—hypertension	2.62e-05	0.000208	CcSEcCtD
Methyldopa—Vomiting—Eplerenone—hypertension	2.62e-05	0.000208	CcSEcCtD
Methyldopa—Leukopenia—Lisinopril—hypertension	2.61e-05	0.000207	CcSEcCtD
Methyldopa—Rash—Fosinopril—hypertension	2.61e-05	0.000207	CcSEcCtD
Methyldopa—Dermatitis—Fosinopril—hypertension	2.61e-05	0.000207	CcSEcCtD
Methyldopa—Epinephrine—ADRB2—hypertension	2.6e-05	0.00669	CrCbGaD
Methyldopa—Vomiting—Nifedipine—hypertension	2.6e-05	0.000206	CcSEcCtD
Methyldopa—Rash—Eplerenone—hypertension	2.6e-05	0.000206	CcSEcCtD
Methyldopa—Headache—Fosinopril—hypertension	2.59e-05	0.000206	CcSEcCtD
Methyldopa—Hypersensitivity—Trandolapril—hypertension	2.59e-05	0.000206	CcSEcCtD
Methyldopa—Dermatitis—Eplerenone—hypertension	2.59e-05	0.000206	CcSEcCtD
Methyldopa—Diarrhoea—Valsartan—hypertension	2.59e-05	0.000206	CcSEcCtD
Methyldopa—Asthenia—Clonidine—hypertension	2.59e-05	0.000206	CcSEcCtD
Methyldopa—Norepinephrine—DRD2—hypertension	2.59e-05	0.00666	CrCbGaD
Methyldopa—L-DOPA—DRD2—hypertension	2.59e-05	0.00666	CrCbGaD
Methyldopa—Vomiting—Verapamil—hypertension	2.59e-05	0.000205	CcSEcCtD
Methyldopa—Hypersensitivity—Enalapril—hypertension	2.58e-05	0.000205	CcSEcCtD
Methyldopa—Body temperature increased—Perindopril—hypertension	2.58e-05	0.000205	CcSEcCtD
Methyldopa—Diarrhoea—Olmesartan—hypertension	2.58e-05	0.000205	CcSEcCtD
Methyldopa—Headache—Eplerenone—hypertension	2.58e-05	0.000205	CcSEcCtD
Methyldopa—Rash—Nifedipine—hypertension	2.58e-05	0.000205	CcSEcCtD
Methyldopa—Nervous system disorder—Ramipril—hypertension	2.58e-05	0.000204	CcSEcCtD
Methyldopa—Dermatitis—Nifedipine—hypertension	2.57e-05	0.000204	CcSEcCtD
Methyldopa—Body temperature increased—Irbesartan—hypertension	2.57e-05	0.000204	CcSEcCtD
Methyldopa—Thrombocytopenia—Ramipril—hypertension	2.57e-05	0.000204	CcSEcCtD
Methyldopa—Oedema—Timolol—hypertension	2.57e-05	0.000204	CcSEcCtD
Methyldopa—Rash—Verapamil—hypertension	2.57e-05	0.000204	CcSEcCtD
Methyldopa—Dermatitis—Verapamil—hypertension	2.56e-05	0.000203	CcSEcCtD
Methyldopa—Headache—Nifedipine—hypertension	2.56e-05	0.000203	CcSEcCtD
Methyldopa—Body temperature increased—Hydrochlorothiazide—hypertension	2.55e-05	0.000203	CcSEcCtD
Methyldopa—Skin disorder—Ramipril—hypertension	2.55e-05	0.000203	CcSEcCtD
Methyldopa—Infection—Timolol—hypertension	2.55e-05	0.000202	CcSEcCtD
Methyldopa—Headache—Verapamil—hypertension	2.55e-05	0.000202	CcSEcCtD
Methyldopa—Hypersensitivity—Telmisartan—hypertension	2.55e-05	0.000202	CcSEcCtD
Methyldopa—Nausea—Diltiazem—hypertension	2.54e-05	0.000202	CcSEcCtD
Methyldopa—Nausea—Indapamide—hypertension	2.54e-05	0.000202	CcSEcCtD
Methyldopa—Asthenia—Trandolapril—hypertension	2.53e-05	0.000201	CcSEcCtD
Methyldopa—Nervous system disorder—Timolol—hypertension	2.52e-05	0.0002	CcSEcCtD
Methyldopa—Nausea—Carvedilol—hypertension	2.52e-05	0.0002	CcSEcCtD
Methyldopa—Asthenia—Enalapril—hypertension	2.52e-05	0.0002	CcSEcCtD
Methyldopa—Body temperature increased—Furosemide—hypertension	2.51e-05	0.000199	CcSEcCtD
Methyldopa—Dizziness—Valsartan—hypertension	2.5e-05	0.000199	CcSEcCtD
Methyldopa—Skin disorder—Timolol—hypertension	2.49e-05	0.000198	CcSEcCtD
Methyldopa—Dizziness—Olmesartan—hypertension	2.49e-05	0.000198	CcSEcCtD
Methyldopa—Nausea—Doxazosin—hypertension	2.49e-05	0.000198	CcSEcCtD
Methyldopa—Arthralgia—Lisinopril—hypertension	2.49e-05	0.000197	CcSEcCtD
Methyldopa—Myalgia—Lisinopril—hypertension	2.49e-05	0.000197	CcSEcCtD
Methyldopa—Body temperature increased—Betaxolol—hypertension	2.48e-05	0.000197	CcSEcCtD
Methyldopa—Asthenia—Telmisartan—hypertension	2.48e-05	0.000197	CcSEcCtD
Methyldopa—Diarrhoea—Clonidine—hypertension	2.47e-05	0.000196	CcSEcCtD
Methyldopa—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—hypertension	2.47e-05	0.000196	CcSEcCtD
Methyldopa—Nausea—Fosinopril—hypertension	2.46e-05	0.000195	CcSEcCtD
Methyldopa—Nausea—Eplerenone—hypertension	2.45e-05	0.000194	CcSEcCtD
Methyldopa—Nausea—Nifedipine—hypertension	2.43e-05	0.000193	CcSEcCtD
Methyldopa—Mesalazine—PTGS2—hypertension	2.42e-05	0.00623	CrCbGaD
Methyldopa—Body temperature increased—Losartan—hypertension	2.42e-05	0.000192	CcSEcCtD
Methyldopa—Dopamine—SLC6A4—hypertension	2.42e-05	0.00623	CrCbGaD
Methyldopa—Nausea—Verapamil—hypertension	2.42e-05	0.000192	CcSEcCtD
Methyldopa—Asthenia—Captopril—hypertension	2.41e-05	0.000192	CcSEcCtD
Methyldopa—Diarrhoea—Trandolapril—hypertension	2.41e-05	0.000191	CcSEcCtD
Methyldopa—Vomiting—Valsartan—hypertension	2.41e-05	0.000191	CcSEcCtD
Methyldopa—Dopamine—DRD2—hypertension	2.41e-05	0.00619	CrCbGaD
Methyldopa—Diarrhoea—Enalapril—hypertension	2.4e-05	0.00019	CcSEcCtD
Methyldopa—Hypersensitivity—Irbesartan—hypertension	2.4e-05	0.00019	CcSEcCtD
Methyldopa—Vomiting—Olmesartan—hypertension	2.4e-05	0.00019	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Ramipril—hypertension	2.39e-05	0.00019	CcSEcCtD
Methyldopa—Rash—Valsartan—hypertension	2.39e-05	0.00019	CcSEcCtD
Methyldopa—Dizziness—Clonidine—hypertension	2.39e-05	0.00019	CcSEcCtD
Methyldopa—Dermatitis—Valsartan—hypertension	2.39e-05	0.000189	CcSEcCtD
Methyldopa—Oedema—Lisinopril—hypertension	2.38e-05	0.000189	CcSEcCtD
Methyldopa—Hypersensitivity—Hydrochlorothiazide—hypertension	2.38e-05	0.000189	CcSEcCtD
Methyldopa—Rash—Olmesartan—hypertension	2.38e-05	0.000189	CcSEcCtD
Methyldopa—Dermatitis—Olmesartan—hypertension	2.37e-05	0.000188	CcSEcCtD
Methyldopa—Headache—Valsartan—hypertension	2.37e-05	0.000188	CcSEcCtD
Methyldopa—Diarrhoea—Telmisartan—hypertension	2.37e-05	0.000188	CcSEcCtD
Methyldopa—Infection—Lisinopril—hypertension	2.37e-05	0.000188	CcSEcCtD
Methyldopa—Headache—Olmesartan—hypertension	2.36e-05	0.000187	CcSEcCtD
Methyldopa—Paraesthesia—Ramipril—hypertension	2.36e-05	0.000187	CcSEcCtD
Methyldopa—Asthenia—Perindopril—hypertension	2.34e-05	0.000186	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Timolol—hypertension	2.34e-05	0.000186	CcSEcCtD
Methyldopa—Hypersensitivity—Furosemide—hypertension	2.34e-05	0.000186	CcSEcCtD
Methyldopa—Asthenia—Irbesartan—hypertension	2.34e-05	0.000185	CcSEcCtD
Methyldopa—Thrombocytopenia—Lisinopril—hypertension	2.33e-05	0.000185	CcSEcCtD
Methyldopa—Dizziness—Trandolapril—hypertension	2.33e-05	0.000185	CcSEcCtD
Methyldopa—Dizziness—Enalapril—hypertension	2.32e-05	0.000184	CcSEcCtD
Methyldopa—Asthenia—Hydrochlorothiazide—hypertension	2.32e-05	0.000184	CcSEcCtD
Methyldopa—Hypersensitivity—Betaxolol—hypertension	2.32e-05	0.000184	CcSEcCtD
Methyldopa—Skin disorder—Lisinopril—hypertension	2.31e-05	0.000184	CcSEcCtD
Methyldopa—Paraesthesia—Timolol—hypertension	2.31e-05	0.000183	CcSEcCtD
Methyldopa—Diarrhoea—Captopril—hypertension	2.3e-05	0.000183	CcSEcCtD
Methyldopa—Vomiting—Clonidine—hypertension	2.3e-05	0.000182	CcSEcCtD
Methyldopa—Dizziness—Telmisartan—hypertension	2.29e-05	0.000182	CcSEcCtD
Methyldopa—Asthenia—Furosemide—hypertension	2.28e-05	0.000181	CcSEcCtD
Methyldopa—Rash—Clonidine—hypertension	2.28e-05	0.000181	CcSEcCtD
Methyldopa—Dermatitis—Clonidine—hypertension	2.27e-05	0.000181	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Ramipril—hypertension	2.27e-05	0.00018	CcSEcCtD
Methyldopa—Headache—Clonidine—hypertension	2.26e-05	0.00018	CcSEcCtD
Methyldopa—Hypersensitivity—Losartan—hypertension	2.26e-05	0.000179	CcSEcCtD
Methyldopa—Asthenia—Betaxolol—hypertension	2.26e-05	0.000179	CcSEcCtD
Methyldopa—Nausea—Valsartan—hypertension	2.25e-05	0.000179	CcSEcCtD
Methyldopa—Constipation—Ramipril—hypertension	2.25e-05	0.000178	CcSEcCtD
Methyldopa—Nausea—Olmesartan—hypertension	2.24e-05	0.000178	CcSEcCtD
Methyldopa—Vomiting—Trandolapril—hypertension	2.24e-05	0.000178	CcSEcCtD
Methyldopa—Diarrhoea—Perindopril—hypertension	2.23e-05	0.000177	CcSEcCtD
Methyldopa—Vomiting—Enalapril—hypertension	2.23e-05	0.000177	CcSEcCtD
Methyldopa—Diarrhoea—Irbesartan—hypertension	2.23e-05	0.000177	CcSEcCtD
Methyldopa—Dizziness—Captopril—hypertension	2.22e-05	0.000177	CcSEcCtD
Methyldopa—Rash—Trandolapril—hypertension	2.22e-05	0.000176	CcSEcCtD
Methyldopa—Dermatitis—Trandolapril—hypertension	2.22e-05	0.000176	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Timolol—hypertension	2.22e-05	0.000176	CcSEcCtD
Methyldopa—Rash—Enalapril—hypertension	2.21e-05	0.000176	CcSEcCtD
Methyldopa—Dermatitis—Enalapril—hypertension	2.21e-05	0.000175	CcSEcCtD
Methyldopa—Diarrhoea—Hydrochlorothiazide—hypertension	2.21e-05	0.000175	CcSEcCtD
Methyldopa—Headache—Trandolapril—hypertension	2.21e-05	0.000175	CcSEcCtD
Methyldopa—Vomiting—Telmisartan—hypertension	2.2e-05	0.000175	CcSEcCtD
Methyldopa—Asthenia—Losartan—hypertension	2.2e-05	0.000174	CcSEcCtD
Methyldopa—Headache—Enalapril—hypertension	2.2e-05	0.000174	CcSEcCtD
Methyldopa—Rash—Telmisartan—hypertension	2.18e-05	0.000173	CcSEcCtD
Methyldopa—Dermatitis—Telmisartan—hypertension	2.18e-05	0.000173	CcSEcCtD
Methyldopa—Diarrhoea—Furosemide—hypertension	2.17e-05	0.000172	CcSEcCtD
Methyldopa—Musculoskeletal discomfort—Lisinopril—hypertension	2.17e-05	0.000172	CcSEcCtD
Methyldopa—Headache—Telmisartan—hypertension	2.17e-05	0.000172	CcSEcCtD
Methyldopa—Dizziness—Perindopril—hypertension	2.16e-05	0.000171	CcSEcCtD
Methyldopa—Dizziness—Irbesartan—hypertension	2.15e-05	0.000171	CcSEcCtD
Methyldopa—Diarrhoea—Betaxolol—hypertension	2.15e-05	0.000171	CcSEcCtD
Methyldopa—Nausea—Clonidine—hypertension	2.14e-05	0.00017	CcSEcCtD
Methyldopa—Paraesthesia—Lisinopril—hypertension	2.14e-05	0.00017	CcSEcCtD
Methyldopa—Vomiting—Captopril—hypertension	2.14e-05	0.00017	CcSEcCtD
Methyldopa—Dizziness—Hydrochlorothiazide—hypertension	2.14e-05	0.000169	CcSEcCtD
Methyldopa—Rash—Captopril—hypertension	2.12e-05	0.000168	CcSEcCtD
Methyldopa—Dermatitis—Captopril—hypertension	2.12e-05	0.000168	CcSEcCtD
Methyldopa—Headache—Captopril—hypertension	2.11e-05	0.000167	CcSEcCtD
Methyldopa—Dizziness—Furosemide—hypertension	2.1e-05	0.000167	CcSEcCtD
Methyldopa—Diarrhoea—Losartan—hypertension	2.1e-05	0.000166	CcSEcCtD
Methyldopa—Nausea—Trandolapril—hypertension	2.09e-05	0.000166	CcSEcCtD
Methyldopa—Nausea—Enalapril—hypertension	2.08e-05	0.000165	CcSEcCtD
Methyldopa—Dizziness—Betaxolol—hypertension	2.08e-05	0.000165	CcSEcCtD
Methyldopa—Vomiting—Perindopril—hypertension	2.08e-05	0.000165	CcSEcCtD
Methyldopa—Body temperature increased—Ramipril—hypertension	2.08e-05	0.000165	CcSEcCtD
Methyldopa—Vomiting—Irbesartan—hypertension	2.07e-05	0.000164	CcSEcCtD
Methyldopa—Rash—Perindopril—hypertension	2.06e-05	0.000163	CcSEcCtD
Methyldopa—Dermatitis—Perindopril—hypertension	2.06e-05	0.000163	CcSEcCtD
Methyldopa—Gastrointestinal disorder—Lisinopril—hypertension	2.06e-05	0.000163	CcSEcCtD
Methyldopa—Nausea—Telmisartan—hypertension	2.05e-05	0.000163	CcSEcCtD
Methyldopa—Vomiting—Hydrochlorothiazide—hypertension	2.05e-05	0.000163	CcSEcCtD
Methyldopa—Rash—Irbesartan—hypertension	2.05e-05	0.000163	CcSEcCtD
Methyldopa—Dermatitis—Irbesartan—hypertension	2.05e-05	0.000163	CcSEcCtD
Methyldopa—Headache—Perindopril—hypertension	2.05e-05	0.000162	CcSEcCtD
Methyldopa—Headache—Irbesartan—hypertension	2.04e-05	0.000162	CcSEcCtD
Methyldopa—Constipation—Lisinopril—hypertension	2.04e-05	0.000162	CcSEcCtD
Methyldopa—Rash—Hydrochlorothiazide—hypertension	2.04e-05	0.000162	CcSEcCtD
Methyldopa—Dermatitis—Hydrochlorothiazide—hypertension	2.03e-05	0.000161	CcSEcCtD
Methyldopa—Body temperature increased—Timolol—hypertension	2.03e-05	0.000161	CcSEcCtD
Methyldopa—Dizziness—Losartan—hypertension	2.03e-05	0.000161	CcSEcCtD
Methyldopa—Headache—Hydrochlorothiazide—hypertension	2.02e-05	0.000161	CcSEcCtD
Methyldopa—Vomiting—Furosemide—hypertension	2.02e-05	0.00016	CcSEcCtD
Methyldopa—Rash—Furosemide—hypertension	2e-05	0.000159	CcSEcCtD
Methyldopa—Dermatitis—Furosemide—hypertension	2e-05	0.000159	CcSEcCtD
Methyldopa—Vomiting—Betaxolol—hypertension	2e-05	0.000159	CcSEcCtD
Methyldopa—Nausea—Captopril—hypertension	2e-05	0.000159	CcSEcCtD
Methyldopa—Headache—Furosemide—hypertension	1.99e-05	0.000158	CcSEcCtD
Methyldopa—Rash—Betaxolol—hypertension	1.98e-05	0.000157	CcSEcCtD
Methyldopa—Dermatitis—Betaxolol—hypertension	1.98e-05	0.000157	CcSEcCtD
Methyldopa—Headache—Betaxolol—hypertension	1.97e-05	0.000156	CcSEcCtD
Methyldopa—Vomiting—Losartan—hypertension	1.95e-05	0.000155	CcSEcCtD
Methyldopa—Nausea—Perindopril—hypertension	1.94e-05	0.000154	CcSEcCtD
Methyldopa—Hypersensitivity—Ramipril—hypertension	1.94e-05	0.000154	CcSEcCtD
Methyldopa—Nausea—Irbesartan—hypertension	1.93e-05	0.000153	CcSEcCtD
Methyldopa—Rash—Losartan—hypertension	1.93e-05	0.000153	CcSEcCtD
Methyldopa—Dermatitis—Losartan—hypertension	1.93e-05	0.000153	CcSEcCtD
Methyldopa—Headache—Losartan—hypertension	1.92e-05	0.000152	CcSEcCtD
Methyldopa—Nausea—Hydrochlorothiazide—hypertension	1.92e-05	0.000152	CcSEcCtD
Methyldopa—Hypersensitivity—Timolol—hypertension	1.89e-05	0.00015	CcSEcCtD
Methyldopa—Nausea—Furosemide—hypertension	1.89e-05	0.00015	CcSEcCtD
Methyldopa—Asthenia—Ramipril—hypertension	1.88e-05	0.00015	CcSEcCtD
Methyldopa—Body temperature increased—Lisinopril—hypertension	1.88e-05	0.000149	CcSEcCtD
Methyldopa—Nausea—Betaxolol—hypertension	1.87e-05	0.000148	CcSEcCtD
Methyldopa—Asthenia—Timolol—hypertension	1.84e-05	0.000146	CcSEcCtD
Methyldopa—Nausea—Losartan—hypertension	1.82e-05	0.000144	CcSEcCtD
Methyldopa—Diarrhoea—Ramipril—hypertension	1.8e-05	0.000143	CcSEcCtD
Methyldopa—Diarrhoea—Timolol—hypertension	1.76e-05	0.000139	CcSEcCtD
Methyldopa—Hypersensitivity—Lisinopril—hypertension	1.76e-05	0.000139	CcSEcCtD
Methyldopa—Dizziness—Ramipril—hypertension	1.74e-05	0.000138	CcSEcCtD
Methyldopa—Asthenia—Lisinopril—hypertension	1.71e-05	0.000136	CcSEcCtD
Methyldopa—Dizziness—Timolol—hypertension	1.7e-05	0.000135	CcSEcCtD
Methyldopa—Vomiting—Ramipril—hypertension	1.67e-05	0.000133	CcSEcCtD
Methyldopa—Rash—Ramipril—hypertension	1.66e-05	0.000131	CcSEcCtD
Methyldopa—Dermatitis—Ramipril—hypertension	1.65e-05	0.000131	CcSEcCtD
Methyldopa—Headache—Ramipril—hypertension	1.65e-05	0.000131	CcSEcCtD
Methyldopa—Vomiting—Timolol—hypertension	1.63e-05	0.00013	CcSEcCtD
Methyldopa—Diarrhoea—Lisinopril—hypertension	1.63e-05	0.000129	CcSEcCtD
Methyldopa—Rash—Timolol—hypertension	1.62e-05	0.000129	CcSEcCtD
Methyldopa—Dermatitis—Timolol—hypertension	1.62e-05	0.000128	CcSEcCtD
Methyldopa—Headache—Timolol—hypertension	1.61e-05	0.000128	CcSEcCtD
Methyldopa—Dizziness—Lisinopril—hypertension	1.58e-05	0.000125	CcSEcCtD
Methyldopa—Nausea—Ramipril—hypertension	1.56e-05	0.000124	CcSEcCtD
Methyldopa—Nausea—Timolol—hypertension	1.53e-05	0.000121	CcSEcCtD
Methyldopa—Vomiting—Lisinopril—hypertension	1.51e-05	0.00012	CcSEcCtD
Methyldopa—Rash—Lisinopril—hypertension	1.5e-05	0.000119	CcSEcCtD
Methyldopa—Dermatitis—Lisinopril—hypertension	1.5e-05	0.000119	CcSEcCtD
Methyldopa—Headache—Lisinopril—hypertension	1.49e-05	0.000118	CcSEcCtD
Methyldopa—Nausea—Lisinopril—hypertension	1.42e-05	0.000112	CcSEcCtD
Methyldopa—ADRA2A—Metabolism—ALDH2—hypertension	4.59e-06	6.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OXTR—hypertension	4.56e-06	6.38e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—GNAS—hypertension	4.55e-06	6.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CR1—hypertension	4.51e-06	6.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TRPC3—hypertension	4.51e-06	6.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CASR—hypertension	4.51e-06	6.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LRP2—hypertension	4.51e-06	6.31e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—ALB—hypertension	4.51e-06	6.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HBA1—hypertension	4.47e-06	6.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADRB2—hypertension	4.46e-06	6.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP11A1—hypertension	4.45e-06	6.22e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTGS2—hypertension	4.44e-06	6.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SERPINE1—hypertension	4.43e-06	6.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB1—hypertension	4.43e-06	6.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CX3CL1—hypertension	4.43e-06	6.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC6—hypertension	4.43e-06	6.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—ALB—hypertension	4.42e-06	6.18e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCE—hypertension	4.4e-06	6.15e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—EDN1—hypertension	4.39e-06	6.13e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTT1—hypertension	4.37e-06	6.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC9A1—hypertension	4.37e-06	6.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCL5—hypertension	4.35e-06	6.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—VAV3—hypertension	4.35e-06	6.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HSPG2—hypertension	4.35e-06	6.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CETP—hypertension	4.32e-06	6.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCLC—hypertension	4.32e-06	6.03e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—NOS3—hypertension	4.31e-06	6.03e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PIK3R1—hypertension	4.31e-06	6.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTH—hypertension	4.31e-06	6.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKG1—hypertension	4.31e-06	6.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADM—hypertension	4.31e-06	6.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GABBR1—hypertension	4.31e-06	6.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDE4D—hypertension	4.31e-06	6.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—RHOA—hypertension	4.27e-06	5.97e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNB3—hypertension	4.24e-06	5.93e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—PIK3R1—hypertension	4.23e-06	5.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—NOS3—hypertension	4.23e-06	5.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GLP1R—hypertension	4.2e-06	5.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TACR1—hypertension	4.2e-06	5.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CYBB—hypertension	4.2e-06	5.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR ligand binding—CXCL8—hypertension	4.19e-06	5.86e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AVP—hypertension	4.19e-06	5.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—ADCY5—hypertension	4.17e-06	5.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCG—hypertension	4.14e-06	5.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP17A1—hypertension	4.13e-06	5.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—GNAS—hypertension	4.13e-06	5.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HRH3—hypertension	4.13e-06	5.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCA—hypertension	4.11e-06	5.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ENO1—hypertension	4.09e-06	5.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS1—hypertension	4.09e-06	5.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EDN1—hypertension	3.98e-06	5.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL5—hypertension	3.95e-06	5.53e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTGS2—hypertension	3.95e-06	5.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CTGF—hypertension	3.94e-06	5.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CCR5—hypertension	3.92e-06	5.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCD—hypertension	3.92e-06	5.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMGCR—hypertension	3.9e-06	5.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GOT2—hypertension	3.9e-06	5.46e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—PTEN—hypertension	3.88e-06	5.42e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCF2—hypertension	3.84e-06	5.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—HTR2A—hypertension	3.84e-06	5.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—C3—hypertension	3.83e-06	5.36e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—ADCY5—hypertension	3.78e-06	5.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Platelet activation, signaling and aggregation—AKT1—hypertension	3.77e-06	5.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCG—hypertension	3.76e-06	5.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NPY—hypertension	3.74e-06	5.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VWF—hypertension	3.74e-06	5.23e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCA—hypertension	3.73e-06	5.22e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—EP300—hypertension	3.7e-06	5.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AGT—hypertension	3.64e-06	5.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL2—hypertension	3.61e-06	5.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—OXT—hypertension	3.61e-06	5.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR1B—hypertension	3.61e-06	5.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR2—hypertension	3.61e-06	5.05e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—TH—hypertension	3.58e-06	5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR1—hypertension	3.57e-06	4.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2R—hypertension	3.57e-06	4.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CALM2—hypertension	3.56e-06	4.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCR5—hypertension	3.56e-06	4.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCD—hypertension	3.56e-06	4.98e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—HTR2A—hypertension	3.48e-06	4.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—C3—hypertension	3.48e-06	4.86e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—SLC2A4—hypertension	3.48e-06	4.86e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GCG—hypertension	3.48e-06	4.86e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRB—hypertension	3.46e-06	4.83e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NCF1—hypertension	3.46e-06	4.83e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—PTEN—hypertension	3.44e-06	4.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TAC1—hypertension	3.42e-06	4.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GOT1—hypertension	3.37e-06	4.71e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—F2—hypertension	3.36e-06	4.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PRKCB—hypertension	3.36e-06	4.7e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ANXA1—hypertension	3.36e-06	4.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCR3—hypertension	3.36e-06	4.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IKBKB—hypertension	3.32e-06	4.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AGT—hypertension	3.31e-06	4.62e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—EP300—hypertension	3.28e-06	4.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—STK11—hypertension	3.27e-06	4.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP19A1—hypertension	3.27e-06	4.57e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDNRA—hypertension	3.26e-06	4.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SST—hypertension	3.26e-06	4.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CALM1—hypertension	3.25e-06	4.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB1—hypertension	3.25e-06	4.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CYBA—hypertension	3.25e-06	4.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FLT1—hypertension	3.25e-06	4.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD3—hypertension	3.25e-06	4.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—EP300—hypertension	3.22e-06	4.5e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GHRL—hypertension	3.18e-06	4.45e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLAT—hypertension	3.18e-06	4.45e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALCA—hypertension	3.14e-06	4.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—SRC—hypertension	3.13e-06	4.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—BDKRB2—hypertension	3.07e-06	4.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—POMC—hypertension	3.06e-06	4.28e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PRKCB—hypertension	3.05e-06	4.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—F2—hypertension	3.05e-06	4.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—VEGFA—hypertension	3.05e-06	4.26e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—COMT—hypertension	3.04e-06	4.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRBK1—hypertension	3.03e-06	4.24e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CNR1—hypertension	3.01e-06	4.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNB3—hypertension	3e-06	4.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARGC1A—hypertension	3e-06	4.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—HMOX1—hypertension	2.98e-06	4.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALM2—hypertension	2.98e-06	4.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT2—hypertension	2.95e-06	4.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAT—hypertension	2.95e-06	4.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR7—hypertension	2.94e-06	4.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—DRD2—hypertension	2.94e-06	4.11e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GNAS—hypertension	2.92e-06	4.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTPN1—hypertension	2.91e-06	4.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GCG—hypertension	2.91e-06	4.07e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOB—hypertension	2.86e-06	4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KL—hypertension	2.85e-06	3.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH2—hypertension	2.85e-06	3.99e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NGFR—hypertension	2.8e-06	3.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGAV—hypertension	2.8e-06	3.92e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TGFB1—hypertension	2.8e-06	3.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KNG1—hypertension	2.79e-06	3.9e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—POMC—hypertension	2.78e-06	3.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GSTM1—hypertension	2.78e-06	3.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGTR1—hypertension	2.78e-06	3.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRL—hypertension	2.78e-06	3.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—STK11—hypertension	2.74e-06	3.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HDAC1—hypertension	2.74e-06	3.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—LPL—hypertension	2.73e-06	3.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CCL2—hypertension	2.72e-06	3.81e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL10—hypertension	2.71e-06	3.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PLG—hypertension	2.7e-06	3.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—RHOA—hypertension	2.7e-06	3.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT2—hypertension	2.67e-06	3.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ADCY5—hypertension	2.67e-06	3.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—PIK3R1—hypertension	2.67e-06	3.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—GPX1—hypertension	2.66e-06	3.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PRKCA—hypertension	2.64e-06	3.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CYP1A1—hypertension	2.64e-06	3.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADRB2—hypertension	2.63e-06	3.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCE—hypertension	2.6e-06	3.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CD36—hypertension	2.59e-06	3.63e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFA—hypertension	2.57e-06	3.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VAV3—hypertension	2.57e-06	3.59e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFBR2—hypertension	2.53e-06	3.54e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNB3—hypertension	2.51e-06	3.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AVP—hypertension	2.47e-06	3.46e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—MTHFR—hypertension	2.46e-06	3.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—RHOA—hypertension	2.45e-06	3.43e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—GNAS—hypertension	2.44e-06	3.41e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—PIK3R1—hypertension	2.43e-06	3.39e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARA—hypertension	2.41e-06	3.37e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOB—hypertension	2.39e-06	3.34e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTK2—hypertension	2.38e-06	3.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—CXCL8—hypertension	2.37e-06	3.31e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EDN1—hypertension	2.35e-06	3.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AGT—hypertension	2.34e-06	3.27e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL5—hypertension	2.33e-06	3.26e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—TP53—hypertension	2.3e-06	3.22e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CALM1—hypertension	2.3e-06	3.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOE—hypertension	2.29e-06	3.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LPL—hypertension	2.28e-06	3.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—CAV1—hypertension	2.27e-06	3.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—H2AFX—hypertension	2.27e-06	3.17e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RPS6KB1—hypertension	2.26e-06	3.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFRB—hypertension	2.26e-06	3.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—APOA1—hypertension	2.26e-06	3.16e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ADCY5—hypertension	2.23e-06	3.12e-05	CbGpPWpGaD
Methyldopa—DDC—Metabolism—AKT1—hypertension	2.23e-06	3.12e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCG—hypertension	2.22e-06	3.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—ITGB3—hypertension	2.2e-06	3.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCA—hypertension	2.2e-06	3.08e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—YWHAZ—hypertension	2.19e-06	3.06e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NGF—hypertension	2.16e-06	3.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SPP1—hypertension	2.16e-06	3.02e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—CXCL8—hypertension	2.15e-06	3.01e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCR5—hypertension	2.1e-06	2.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCD—hypertension	2.1e-06	2.94e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HTR2A—hypertension	2.06e-06	2.88e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—C3—hypertension	2.06e-06	2.87e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PDGFB—hypertension	2e-06	2.8e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PPARG—hypertension	1.99e-06	2.79e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGFR1—hypertension	1.99e-06	2.78e-05	CbGpPWpGaD
Methyldopa—COMT—Metabolism—AKT1—hypertension	1.98e-06	2.77e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—POMC—hypertension	1.97e-06	2.75e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—HIF1A—hypertension	1.96e-06	2.74e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—INS—hypertension	1.95e-06	2.73e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AGT—hypertension	1.95e-06	2.73e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Hemostasis—AKT1—hypertension	1.94e-06	2.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CALM1—hypertension	1.92e-06	2.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—LEP—hypertension	1.91e-06	2.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOE—hypertension	1.91e-06	2.68e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CAV1—hypertension	1.9e-06	2.65e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—APOA1—hypertension	1.89e-06	2.64e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—KDR—hypertension	1.87e-06	2.62e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FN1—hypertension	1.8e-06	2.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PRKCB—hypertension	1.8e-06	2.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—F2—hypertension	1.8e-06	2.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—ALB—hypertension	1.79e-06	2.51e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOTCH1—hypertension	1.77e-06	2.47e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PIK3R1—hypertension	1.71e-06	2.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—NOS3—hypertension	1.71e-06	2.4e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—POMC—hypertension	1.64e-06	2.3e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—INS—hypertension	1.63e-06	2.29e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CCL2—hypertension	1.61e-06	2.25e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IGF1—hypertension	1.58e-06	2.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT2—hypertension	1.58e-06	2.21e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—EGFR—hypertension	1.57e-06	2.2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTGS2—hypertension	1.57e-06	2.19e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SERPINE1—hypertension	1.5e-06	2.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—FGF2—hypertension	1.45e-06	2.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RHOA—hypertension	1.45e-06	2.03e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PIK3R1—hypertension	1.43e-06	2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—NOS3—hypertension	1.43e-06	2e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—PTEN—hypertension	1.37e-06	1.91e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—RELA—hypertension	1.35e-06	1.89e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MTOR—hypertension	1.32e-06	1.85e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—EP300—hypertension	1.3e-06	1.82e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CXCL8—hypertension	1.27e-06	1.78e-05	CbGpPWpGaD
Methyldopa—ADRA2A—GPCR downstream signaling—AKT1—hypertension	1.23e-06	1.72e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—IL6—hypertension	1.21e-06	1.69e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MMP9—hypertension	1.15e-06	1.61e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—CDKN1A—hypertension	1.15e-06	1.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—PTEN—hypertension	1.14e-06	1.6e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MAPK8—hypertension	1.12e-06	1.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling by GPCR—AKT1—hypertension	1.12e-06	1.56e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EP300—hypertension	1.09e-06	1.52e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—SRC—hypertension	1.06e-06	1.48e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—VEGFA—hypertension	1.03e-06	1.44e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—MYC—hypertension	9.5e-07	1.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TGFB1—hypertension	9.48e-07	1.33e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—EGFR—hypertension	9.29e-07	1.3e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Metabolism—AKT1—hypertension	7.88e-07	1.1e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—TP53—hypertension	7.8e-07	1.09e-05	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—IL6—hypertension	7.14e-07	9.99e-06	CbGpPWpGaD
Methyldopa—ADRA2A—Signaling Pathways—AKT1—hypertension	6.59e-07	9.21e-06	CbGpPWpGaD
